Q: Where did you grow up?
Growing up, I was a bit backwards and spent my winters in Minnesota and my summers in Florida. In adulthood, though, I realized
…
Month: September 2023
SPONSORED CONTENT
TIP: Be prepared to answer 340B claims eligibility questions in an audit.
Covered entities need to be
While federal regulators recently extended the comment period on a proposed lump sum repayment plan for hospitals Illegally underpaid for [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Draft legislation that would exclude some generics from 340B and focus on penny pricing recently drew criticism from provider advocates. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
An update on new reporting requirements and the continuous program compliance imperative
The integrity of the 340B drug discount program is under a microscope. Two states have recently passed laws requiring 340B providers to report on how they are utilizing their savings and national legislation has passed a key committee in the U.S. House of Representatives. Covered entities must act now to demonstrate that they are good program stewards and be prepared for additional reporting requirements.
As a bipartisan group of U.S. senators reviews responses to a congressional RFI seeking input on how to improve the 340B program, Sectyr is launching an informative webinar series designed to shed light on one of the group’s most pressing questions: How to improve the accountability of the 340B program and give policymakers and industry stakeholders greater confidence in its oversight.
On September 13, join Ted
…
The drug industry group challenging the legality of Arkansas’ 340B contract pharmacy law, notified a federal appeals court that the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Tolmar recently said it plans refunds to 340B covered entities for overcharges on seven generic dermatologic products purchased [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
For 340B program directors, complying with the U.S. Health Resources & Services Administration’s (HRSA’s) requirements is top of mind, all the time. That’s partly because maintaining their employer’s 340B program directly ties to profitability and sometimes survival. Covered entities need 340B revenue to meet the program’s purpose “to stretch scare resources as far possible, reach more eligible patients and provide more comprehensive services.” Complying with the program requires a constant focus on guidelines and regulations.
Along with protecting program benefits and monitoring changing requirements, 340B program managers also hear politicians, pharmaceutical manufacturers and the press call for more oversight by the federal government. Manufacturers are concerned about program growth. According to HRSA, discounted purchases under the 340B Program hit $44 billion in 2021, a 16-percent uptick from 2020. The volume may have slowed down with the recent manufacturer restrictions on use of 340B discounts in the contract pharmacy setting but
…
Belgium drug maker UCB will add restrictions on 340B contract pharmacy use for hospitals starting Oct. 2, according to a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer EMD Serono (EMDS) today announced 340B contract pharmacy restrictions for hospitals will expand Oct. 1 to all of [...] …